Tvardi Therapeutics Inc (TVRD)

May 05, 2026

MSN Money - MSN

May 05, 2026

May 02, 2026

Tvardi Therapeutics Files $200 Million Mixed Shelf - Moomoo

May 02, 2026

May 01, 2026

Tvardi Therapeutics (NASDAQ: TVRD) registers $200M shelf, $12.5M ATM - Stock Titan

May 01, 2026

Apr 29, 2026

Is Tvardi Therapeutics (TVRD) stock breaking out | Q4 2025: EPS Misses EstimatesInvestment Signal Network - Newser

Apr 29, 2026

Apr 29, 2026

Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN

Apr 29, 2026

Apr 26, 2026

TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 26, 2026

Apr 24, 2026

Tvardi Therapeutics posts 18.3% downside EPS miss amid clinical trial costsEarnings Forecast - Newser

Apr 24, 2026

Apr 23, 2026

Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors - Stock Titan

Apr 23, 2026

Apr 21, 2026

Barclays downgrades Tvardi Therapeutics (TVRD) - MSN

Apr 21, 2026

Apr 20, 2026

Tvardi Therapeutics Shares Drop After Downgrade From Barclays - Moomoo

Apr 20, 2026

Apr 20, 2026

Barclays Downgrades Tvardi Therapeutics to Underweight From Equalweight, Adjusts Price Target to $3 From $4 - Moomoo

Apr 20, 2026

Apr 20, 2026

Barclays cuts Tvardi Therapeutics stock rating on funding concerns - Investing.com

Apr 20, 2026

Apr 20, 2026

Barclays cuts Tvardi Therapeutics stock rating on funding concerns By Investing.com - Investing.com Canada

Apr 20, 2026

Apr 16, 2026

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Unlocking 140% Upside Potential in the Biotech Sector - DirectorsTalk Interviews

Apr 16, 2026

Apr 15, 2026

Pulmonary Fibrosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeut - Barchart.com

Apr 15, 2026

Apr 13, 2026

Published on: 2026-04-13 19:29:33 - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Weekly Trades: What hedge funds are buying Tvardi Therapeutics IncPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

TVRD Options Volatility — NASDAQ:TVRD - TradingView

Apr 11, 2026

Apr 09, 2026

Portfolio Shifts: What hedge funds are buying Tvardi Therapeutics IncTrade Entry Summary & Community Verified Swing Trade Signals - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Analysis Recap: Is Tvardi Therapeutics Inc attractive at current valuation2026 Highlights & Entry and Exit Point Strategies - baoquankhu1.vn

Apr 08, 2026

Apr 04, 2026

Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen - Defense World

Apr 04, 2026

Apr 03, 2026

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - Sahm

Apr 03, 2026

Apr 03, 2026

BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD) - Defense World

Apr 03, 2026

Apr 02, 2026

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail

Apr 02, 2026

Apr 02, 2026

Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD) - The Globe and Mail

Apr 02, 2026

Apr 02, 2026

Barclays Lowers Price Target for Tvardi Therapeutics (TVRD) | TV - GuruFocus

Apr 02, 2026

Apr 02, 2026

Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development - TipRanks

Apr 02, 2026

Apr 01, 2026

Tvardi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets

Apr 01, 2026

Apr 01, 2026

Tvardi Therapeutics (TVRD) Sees Price Target Cut by Piper Sandler | TVRD Stock News - GuruFocus

Apr 01, 2026

Apr 01, 2026

Piper Sandler cuts Tvardi Therapeutics price target on trial timing By Investing.com - Investing.com India

Apr 01, 2026

Apr 01, 2026

Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock By Investing.com - Investing.com South Africa

Apr 01, 2026

Apr 01, 2026

Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock - Investing.com

Apr 01, 2026

Apr 01, 2026

Piper Sandler cuts Tvardi Therapeutics price target on trial timing - Investing.com

Apr 01, 2026

Apr 01, 2026

Tvardi Therapeutics (NASDAQ: TVRD) registers 2,084,117 resale shares; clinical updates - Stock Titan

Apr 01, 2026

Apr 01, 2026

Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment - Stock Titan

Apr 01, 2026

Mar 31, 2026

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update - Bitget

Mar 31, 2026

Mar 31, 2026

Tvardi: Q4 Earnings Snapshot - Barchart.com

Mar 31, 2026